Oncology – Urological
RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer
15 Jan, 2023 | 20:05h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023
Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
11 Jan, 2023 | 14:10h | UTC5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
?1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3
— Shankar Siva (@_ShankarSiva) November 16, 2022
Review | Advances in diagnosis and treatment of testicular cancer.
16 Dec, 2022 | 13:25h | UTCAdvances in diagnosis and treatment of testicular cancer – The BMJ
Podcast | Prostate cancer: screening, advanced testing, and survivorship.
14 Dec, 2022 | 14:48h | UTC#371 Prostate Cancer: Screening, Advanced Testing, and Survivorship – The Curbsiders
RCT | Rogaratinib vs. chemotherapy in patients with advancer urothelial carcinoma selected based on FGFR1/3 mRNA expression.
14 Dec, 2022 | 14:45h | UTC
Commentary on Twitter
? FORT-1: Rogaratinib achieves similar response and overall survival as standard chemotherapy in patients with locally advanced or metastatic #UrothelialCarcinoma selected based on FGFR1/3 mRNA expression ? https://t.co/5KAIGpCSt6 #JCO #kcsm #blcsm @cnsternberg pic.twitter.com/jDfVzfwr4e
— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2022
RCT | Effects of prostate cancer screening with PSA and MRI followed by targeted biopsy only.
9 Dec, 2022 | 13:32h | UTCProstate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: New prostate cancer diagnostic pathway paves way for general screening – University of Gothenburg
Commentary: MRI-Targeted Biopsy Beneficial for Men With Elevated PSA – HealthDay
Commentary on Twitter
In a prostate-cancer screening trial involving men with lesions shown on MRI, targeted biopsy alone detected half as many clinically insignificant tumors as targeted and systematic biopsy, with few significant tumors missed. https://t.co/1H6pRN4aLR pic.twitter.com/yy3PAtYuZK
— NEJM (@NEJM) December 8, 2022
RCT | Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer.
9 Dec, 2022 | 13:15h | UTCDaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer – Cancer Therapy Advisor
Commentary on Twitter
✅ DaBlaCa-13: Oncological outcome of short-term, intensive chemoresection with mitomycin C in non muscle invasive #BladderCancer ? https://t.co/G7jmPNyaao #JCO #blcsm @SkydtLindgren @JBjerggaard @LDyrskjot @NessnAzawi pic.twitter.com/KHn4gOHtnv
— Journal of Clinical Oncology (@JCO_ASCO) October 28, 2022
RCT | Olaparib with or without Cediranib for metastatic castration-resistant prostate cancer.
9 Dec, 2022 | 13:14h | UTCCommentary: Olaparib Plus Cediranib for mCRPC Lowers Radiographic Progression Risk – Renal & Urology News
Commentary on Twitter
Olaparib (#PARPi) combined with cediranib improved median radiographic PFS compared to olaparib alone in metastatic castrate-resistant #ProstateCancer ? https://t.co/guuQ0QQwfL #JCO #PCSM @Joseph_W_Kim pic.twitter.com/jr3GHHrndM
— Journal of Clinical Oncology (@JCO_ASCO) November 1, 2022
18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.
22 Nov, 2022 | 13:09h | UTCIntra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given radioisotope therapy for prostate cancer.
22 Nov, 2022 | 12:56h | UTCPSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC – Targeted Oncology
Guideline | Management of castration-resistant prostate cancer.
17 Nov, 2022 | 12:28h | UTC
RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.
11 Nov, 2022 | 13:55h | UTC[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting
RCT | Photodynamic vs. white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer.
31 Oct, 2022 | 13:51h | UTC
[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.
27 Oct, 2022 | 12:32h | UTCNews Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting
RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.
27 Oct, 2022 | 12:23h | UTCContinuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
RCT | Effect of peritoneal fixation on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy.
24 Oct, 2022 | 14:05h | UTCEffect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Articles in Press: Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial https://t.co/QdWtFGJcnm @VladaStudent @SeifriedovaZ @studentova #medtwitter pic.twitter.com/2YvaxxVcVR
— European Urology (@EUplatinum) October 15, 2022
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.
Post-trial follow-up | Metastasis-directed therapy vs. observation in oligometastatic prostate cancer.
18 Oct, 2022 | 12:47h | UTCCommentary: Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term – Cancer Therapy Advisor
Commentary on Twitter
? #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
? Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost https://t.co/OO8kcTVvFT pic.twitter.com/FqxGisz34F— Journal of Clinical Oncology (@JCO_ASCO) September 19, 2022
Single-arm phase 2 study | A less intensive treatment strategy may be effective for patients with stage IIA and stage IIB seminoma.
17 Oct, 2022 | 12:25h | UTCSingle-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: De-escalation Strategy in Seminoma: An Alternative Option? – Medscape (free registration required)
Commentary on Twitter
??
SAKK 01/10 results are out!! ??Stage IIA/B testicular seminoma➡️
1️⃣cycle of carboplatin+involved node RT
116 pts, median FU 4.5yrs
3yr PFS 93.7%, 7 relapses, all successfully salvaged. Seminoma-specific surv ?%
Generally well tolerated, gr3+tox chemo-related https://t.co/vI6ipafhZ8— Sophia Kamran, MD (@sophia_kamran) October 11, 2022
M-A | Addition of androgen receptor targeted agents to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer.
27 Sep, 2022 | 13:02h | UTC
Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.
21 Sep, 2022 | 13:10h | UTC
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial ? 2 year toxicity results of PACE B published here. Big thanks to the ???? and??collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree ??? (@alison_tree) September 14, 2022
ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.
19 Sep, 2022 | 12:31h | UTC
Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.
15 Sep, 2022 | 13:11h | UTCInvited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open
RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.
11 Sep, 2022 | 22:52h | UTCCommentaries:
Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology
Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News
Commentary on Twitter
In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022